Document Detail


Revisions to the general safety requirements for biological products; companion document to direct final rule--FDA. Proposed rule.
MedLine Citation:
PMID:  10178870     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Food and Drug Administration (FDA) is proposing to amend the biologics regulations by adding cellular therapy products to the list of products exempted from the general safety test (GST) and by adding an administrative procedure for obtaining exemptions from the GST requirements. This proposed rule is a companion document to the direct final rule published elsewhere in this issue of the Federal Register. FDA is taking this action because the GST may not be relevant or necessary for many types of biological products, including cellular therapy products, currently in various stages of development.
Authors:
-
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Federal register     Volume:  63     ISSN:  0097-6326     ISO Abbreviation:  Fed Regist     Publication Date:  1998 Apr 
Date Detail:
Created Date:  1998-06-17     Completed Date:  1998-06-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7808722     Medline TA:  Fed Regist     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  19431-4     Citation Subset:  H    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Products*
Device Approval / legislation & jurisprudence*,  standards
Equipment Safety
Guidelines as Topic
Policy Making
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Biological Products

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Revisions to the general safety requirements for biological products--FD. Direct final rule.
Next Document:  Medicare program; scope of Medicare benefits and application of the outpatient mental health treatme...